Catalyst Pharmaceuticals (CPRX) Accounts Payables (2010 - 2026)

Catalyst Pharmaceuticals' Accounts Payables history runs 17 years deep, the most recent figure standing at $7.2 million for Q1 2026.

• Quarterly Accounts Payables fell 36.13% year-over-year to $7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.2 million (down 36.13% YoY) and the FY2025 annual result came in at $11.2 million, down 32.49% from the prior year.
• Accounts Payables was $7.2 million for Q1 2026 at Catalyst Pharmaceuticals, down from $11.2 million in the prior quarter.
• Across five years, Accounts Payables topped out at $16.6 million in Q4 2024 and bottomed at $2.3 million in Q2 2022.
• A 5-year average of $7.7 million and a median of $7.1 million in 2024 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2023 — Accounts Payables soared 272.2% — and 2026, when it tumbled 36.13%.
• Catalyst Pharmaceuticals' Accounts Payables stood at $4.0 million in 2022, then surged by 272.2% to $14.8 million in 2023, then grew by 12.15% to $16.6 million in 2024, then slumped by 32.49% to $11.2 million in 2025, then plunged by 36.16% to $7.2 million in 2026.
• Business Quant data shows CPRX's Accounts Payables at $7.2 million in Q1 2026, $11.2 million in Q4 2025, and $9.1 million in Q3 2025.